CTOs on the Move

Samumed

www.samumed.com

 
Samumed is a leader in medical research and development for tissue-level regeneration. With our platform`s origins in small molecule-based Wnt pathway modulation, we develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Samumed raised $438M on 08/06/2018

Similar Companies

BioReliance Corporation

BioReliance Corporation is a contract service organization that provides services for biologics and other biomedical products to biotechnology and pharmaceutical companies worldwide. The Company has two segments, testing and development services and

Phosplatin Therapeutics

Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia.

Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors. The company will soon begin enrolling MAT9001 in a confirmatory head-to-head PK/PD study vs Vascepa, after having shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels in a previous study, with data expected in Q42020. In addition, the Company is developing MAT2203, an oral, encochleated formulation of Amphotericin B, to treat serious invasive fungal infections. The drug is based on Matinas` proprietary lipid nano-crystal (“LNC”) platform technology which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable.

Recombinetics

Recombinetics is a global leader in proprietary gene repair and gene-editing technology. Our breakthrough scientific research and development of TALEN and CRISPR (Cas9) gene editing technologies has resulted in breakthroughs in the regenerative medicine, disease research and animal agriculture.

PharmaSeq

PharmaSeq is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.